DEVELOPING PHARMACOLOGICAL TGLI1 INHIBITORS FOR THE TREATMENT OF METASTATIC BREAST CANCER
Electronic Theses and Dissertations
Item Files
Item Details
- abstract
- Breast cancer remains the second leading cause of cancer-related death in women and second most common cancer to metastasize to the brain. Despite improvements in early detection and targeted therapies, breast cancer patients with brain metastases survive a median of 4-6 months underscoring the clinical need to develop new therapeutic strategies and identify novel actionable targets. The aim of this study is to revolutionize breast cancer treatment regimens by characterizing novel combinations of FDA-approved therapies to provide translatable results, and by developing small molecule inhibitors against a key driver of breast cancer brain metastases (BCBM), truncated glioma-associated oncogene homolog 1 (tGLI1).
- subject
- breast cancer
- breast cancer brain metastasis
- breast cancer stem cells
- GLI1
- small molecules
- tGLI1
- contributor
- Lo, Hui-Wen (committee chair)
- Metheny-Barlow, Linda J. (committee member)
- Furdui, Cristina M. (committee member)
- Smalley, Terrence L. (committee member)
- Strowd, Roy E. (committee member)
- Watabe, Kounosuke (committee member)
- date
- 2022-05-24T08:36:12Z (accessioned)
- 2022 (issued)
- degree
- Cancer Biology (discipline)
- 2024-05-23 (liftdate)
- embargo
- 2024-05-23 (terms)
- identifier
- http://hdl.handle.net/10339/100773 (uri)
- language
- en (iso)
- publisher
- Wake Forest University
- title
- DEVELOPING PHARMACOLOGICAL TGLI1 INHIBITORS FOR THE TREATMENT OF METASTATIC BREAST CANCER
- type
- Dissertation